NCT02283177: A trial that was reported late by Arog Pharmaceuticals, Inc.
This trial has reported, although it was 1104 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT02283177 |
|---|---|
| Title | A Safety and Tolerability Trial of Crenolanib and Chemotherapy With Cytarabine and Anthracyclines in Patients With Newly Diagnosed Acute Myeloid Leukemia With FLT3 Activating Mutations |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Jan. 31, 2015 |
| Completion date | Dec. 31, 2019 |
| Required reporting date | Dec. 30, 2020, midnight |
| Actual reporting date | Jan. 9, 2024 |
| Date last checked at ClinicalTrials.gov | Dec. 3, 2025 |
| Days late | 1104 |